Annual report for Indraprastha Medical Corporation Ltd. for FY-2023
23-05-2023
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit Annual Secretarial Compliance Report from a practicing Company Secretary, for the year ended 31st March, 2023. This is for your information and record.16-05-2023
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 read with Schedule III (Part A) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit copies of the public notice of the date of the Board meeting, published on 12th May, 2023, in the 'Financial Express', all India editions, in English language and in 'Jansatta', Delhi edition, in Hindi language. You are requested to take the above information on record.12-05-2023
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Board Meeting Intimation for Board Meeting To Consider And Approve Audited Financial Results And Dividend, If Any, For The Financial Year 2022-23
INDRAPRASTHA MEDICAL CORP.LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/05/2023 ,inter alia, to consider and approve Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is hereby informed that a meeting of the Board of Directors of the Company will be held on Tuesday, 23rd May, 2023, inter alia: - a) to consider and approve the audited financial results for the quarter/ year ended 31st March, 2023; and b) to consider and recommend dividend, if any, on equity shares of the Company for the financial year 2022-23.11-05-2023
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyINDRAPRASTHA MEDICAL CORP.LTD. 2CIN NO.L24232DL1988PLC030958 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY AA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)ICRA LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: PRIYA RANJAN Designation: AVP CORPORATE AFFAIRS LEGAL EmailId: [email protected] Name of the Chief Financial Officer: C P TYAGI Designation: CHIEF FINANCIAL OFFICER EmailId: [email protected] Date: 26/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.26-04-2023
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Announcement under Regulation 30 (LODR)-Credit Rating
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that ICRA Limited has given long term credit ratings at [ICRA]AA (pronounced ICRA Double A) for Rs. 62.50 crore bank facilities and short term credit ratings at [ICRA]A1+ (pronounced ICRA A One Plus) for Rs. 40.0 crore Commercial Paper to the Company.15-04-2023
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Compliance Certificate Under Regulation 40(10)
Pursuant to Regulation 40(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed please find a copy of the certificate from a practicing Company Secretary certifying that all certificates have been issued, for the financial year ended 31st March, 2023, within 30 days of the date of lodgment for15-04-2023
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Compliance Certificate For The Period Ended 31St March, 2023
Pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed please find the compliance certificate for the period 1st April, 2022 to 31st March, 2023.13-04-2023
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, enclosed please find herewith a Certificate dated 5th April, 2023, issued by M/s. Link Intime India Private Limited, Registrar & Share Transfer Agent of the Company, for the quarter ended 31st March, 2023.13-04-2023
INDRAPRASTHA MEDICAL CORP.LTD. - 532150 - Closure of Trading Window
Pursuant to the provisions of the Code of Conduct for Prevention of Insider Trading, under SEBI (Prohibition of Insider Trading) Regulations, 2015, it is hereby informed that Trading Window for dealing in shares of the Company, will remain closed with effect from 1st April, 2023 till 48 hours after the declaration of audited financial results for the quarter / year ending 31st March, 2023. The date of the Board Meeting to consider the audited financial results for the quarter / financial year ending 31st March, 2023, shall be intimated separately.23-03-2023